[A case of papillary adenocarcinoma of the ovary that responded favorably to irinotecan hydrochloride and cisplatin after the administration of paclitaxel and carboplatin].

Abstract

Recently, the standard treatment for advanced ovarian cancer has changed from CP therapy (cyclophosphamide, cisplatin (CDDP)) to TJ therapy (paclitaxel (TXL), carboplatin (CBDCA)). Irinotecan (CPT-11) is one of the derivatives of camptotecin and has been reported to have a high efficacy for ovarian cancer. In one case of ovarian cancer, chemotherapy was applied with CBDCA and TXL. However, after 2 months of six courses of the chemotherapy, CA-125 was elevated. The elevation of tumor marker levels in serum without the recurrent focus forced us to treat the patient with CPT-11 and CDDP for the second line chemotherapy. Tumor marker levels improved at the beginning of the therapy. In conclusion, CPT-11 and CDDP was effective against the recurrence of ovarian cancer treated with TJ therapy.

• Authors: K Shimoya, I Kunishige, Y Okuno, S Hayashi, H Komura, Y Arimoto, Y Otsuki
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 28 Issue 6 Pg. 845-8 (Jun 2001) ISSN: 0385-0684 [Print] Japan
• PMID: 11432356 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents, Phytogenic
• Biomarkers, Tumor
• Irinotecan
• Cyclophosphamide
• Carboplatin
• Paclitaxel
• Cisplatin
• Camptothecin

Topics

• Adenocarcinoma, Papillary (drug therapy)
• Antineoplastic Agents, Phytogenic (therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
• Biomarkers, Tumor (blood)
• Camptothecin (administration & dosage, analogs & derivatives)
• Carboplatin (administration & dosage)
• Cisplatin (administration & dosage)
• Cyclophosphamide (administration & dosage)
• Female
• Humans
• Irinotecan
• Middle Aged
• Ovarian Neoplasms (drug therapy)
• Paclitaxel (administration & dosage)
• Treatment Outcome